公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2022 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma | Zhu A.X.; Abbas A.R.; de Galarreta M.R.; Guan Y.; Lu S.; Koeppen H.; Zhang W.; CHIH-HUNG HSU ; He A.R.; Ryoo B.-Y.; Yau T.; Kaseb A.O.; Burgoyne A.M.; Dayyani F.; Spahn J.; Verret W.; Finn R.S.; Toh H.C.; Lujambio A.; Wang Y. | Nature Medicine | 108 | 115 | |
2013 | Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma | Toh H.C.; PEI-JER CHEN ; Carr B.I.; Knox J.J.; Gill S.; Ansell P.; McKeegan E.M.; Dowell B.; Pedersen M.; Qin Q.; Qian J.; Scappaticci F.A.; Ricker J.L.; Carlson D.M.; Yong W.P. | Cancer | 102 | 89 |